chest pain; this case was received (reference number: gb-mhra-adr 26656059) on 27-feb-2022 and was forwarded to moderna on 27-feb-2022. this regulatory authority case was reported by a consumer and describes the occurrence of chest pain (chest pain) in a 50-year-old female patient who received mrna-1273 (moderna covid-19 vaccine) for adverse drug reaction nos. no medical history information was reported. on 17-jan-2022, the patient received first dose of mrna-1273 (moderna covid-19 vaccine) (unknown route) 1 dosage form. on 17-jan-2022, received dose of mrna-1273 (moderna covid-19 vaccine) (unknown route) dosage was changed to 1 dosage form. on 17-jan-2022, the patient experienced chest pain (chest pain) (seriousness criterion medically significant). on 25-feb-2022, chest pain (chest pain) had resolved with sequelae. date of lmp: 14-feb-2022 no concomitant medications were reported. patient was not pregnant and not currently breastfeeding. patient had vomiting, palpitations, sweats and shivering, fever, muscle and bone ache, migraines, light sensitivity, pressure in eyes and inability to read print. extreme fatigue. menstrual disruption. no treatment medications were reported. reported that reaction does not occurred as a result of a mistake made in the administration of the vaccine. this is a regulatory case concerning a 50-year-old female patient with no medical history, who experienced the unexpected serious event of chest pain. the event was medically significant as reported by the regulatory authority and occurred the same day after receiving the first dose of mrna-1273 vaccine. no clinical or treatment details were given. it was reported that the outcome of the event has resolved with sequelae. the benefit-risk relationship of mrna-1273 vaccine is not affected by this report.; sender's comments: this is a regulatory case concerning a 50-year-old female patient with no medical history, who experienced the unexpected serious event of chest pain. the event was medically significant as reported by the regulatory authority and occurred the same day after receiving the first dose of mrna-1273 vaccine. no clinical or treatment details were given. it was reported that the outcome of the event has resolved with sequelae. the benefit-risk relationship of mrna-1273 vaccine is not affected by this report